|
Renin-Angiotensin-Aldosterone axis inhibition improves outcome of diabetic patients with chronic hypertension and COVID-19: An Iranian perspective
Zahedin Kheyri1, Mahboobeh Alizadeh2, Samaneh Akbarpour3, Hadiseh Hosamirudsari4, Mohammad H K Niya5, Fatemeh Aliasgharpour6, Mohadeseh M Meidan6, Shahrbanoo Hassanzadeh1, Razieh Dowran7, Ali Jafarpour8
1 Department of Internal Medicine, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Infectious Disease Department, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 Occupational Sleep Research Center, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Infectious Disease, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
5 Gastrointestinal and Liver Diseases Research Center; Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
6 School of Medicine; Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
7 Department of Virology, School of Public Health; Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran
8 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Correspondence Address:
Dr. Hadiseh Hosamirudsari
Department of Infectious Disease, Baharloo Hospital, Tehran University of Medical Sciences, Tehran
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/abr.abr_177_21
|
|
Background: Safe use of drugs such as angiotensin-converting enzyme 2 (ACE2) inhibitors and angiotensin receptor blockers (ARBs) in COVID diabetic patients needs comprehensive studies. This study addressed this issue from the Iranian perspective.
Materials and Methods: Admitted COVID-19 patients were divided into four groups in this historical cohort study. Group 1 included 740 non-diabetic, non-hypertensive patients. Group 2 included 132 non-hypertensive diabetic patients. Group 3 included 154 non-diabetic hypertensive patients. Group 4 included 183 diabetic patients who were under ACE inhibitors or ARBs. Death, intensive care unit (ICU) admission, and length of hospitalization were compared between the groups.
Results: After considering associated factors such as age, gender, dyslipidemia, cardiovascular diseases, rheumatoid arthritis (RA), chronic kidney disease (CKD), history of surgery, and corticosteroid use, diabetic patients (group 2) were associated with increased mortality (CI 95%, OR 1.93 [1.11–3.33]). Presence of diabetes (group 2) and hypertension were associated with an increased need for ICU admission (CI 95%, OR 1.69 [1.04–2.76]; CI 95%, OR 1.71 [1.08–2.71], respectively). Group 4 patients although having a similar rate of ICU admission with group 2 and 3 patients, had significantly better ICU survival.
Conclusions: The current study suggests that ACE inhibitors and ARBs are associated with decreased mortality, ICU admission, and better ICU survival in the diabetic subgroup of hypertensive patients.
|
